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10Hydrothermal duodenal mucosal resurfacing: a novel
procedural therapy for metabolic diseasere 1. Images from a 43-year-old man with type 2 diabetes who underwent hydrothermal double mucosal resurfacing. During the procedure, the
enum is sized and (A) the mucosa is lifted circumferentially. Mucosal lifting is followed by hydrothermal ablation of the mucosa (B) to stimulate
eration.This video demonstrates Revita duodenal mucosal
resurfacing (DMR; Fractyl Laboratories, Inc, Waltham,
Mass), an investigational, catheter-based, upper endo-
scopic procedure for the treatment of metabolic diseases,
including type 2 diabetes (T2D) and nonalcoholic steato-
hepatitis (Video 1, available online at www.VideoGIE.
org). The procedure uses hydrothermal ablation of
approximately 10 cm of duodenal mucosa to elicit
beneﬁcial metabolic effects, including improvements in
hyperglycemia in patients with T2D who are suboptimally
controlled on oral antidiabetic medications. This video
provides an overview of the procedure and describes the
6-month clinical results of a 43-year-old man (duration of
T2D, 6 years) treated with DMR. At screening, the patient
had a body mass index of 31, weight of 91.6 kg, hemoglo-
bin A1c of 9.5%, and fasting plasma glucose (FPG) of 162
mg/dL. Six months after a single hydrothermal DMR pro-
cedure, the patient’s hemoglobin A1c had fallen to 7.2%
and FPG had fallen to 132 mg/dL. The patient experienced
a modest weight reduction (–2.3 kg), and his use of oral
antidiabetic medications (nZ 2) did not change. Liver en-
zymes, followed as a safety signal, remained normal.
Follow-up endoscopy at 90 days indicated full mucosal
healing. Figure 1 depicts the duodenal mucosa (A) afteren transcript of the video audio is available online at www.VideoGIE.org.
VIDEOGIE Volume 1, No. 1 : 2016saline solution lift and (B) after ablation. We conclude
that DMR may provide the ability to improve
hyperglycemia in T2D and may offer a novel
nonpharmacologic treatment of metabolic disease.
Further study is needed to evaluate the long-term safety,
efﬁcacy, and durability of this procedure.DISCLOSURE
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